

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Applicant	: Fernando Bouffard Fita	Confirmation No. : 8090
Application No.	: 10/562,392	Group Art Unit: 1615
Filed	: December 19, 2005	Examiner : not yet assigned
Title	: Anesthetic Composition for Topical Administration Comprising Lidocaine, Prilocaine and Tetracaine	

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attn : Office of Initial Patent Examinations
Filing Receipt Corrections

Dear Sir:

Applicant respectfully notes that the Filing Receipt, mailed on April 18, 2007, see Exhibit 1, for the above-identified patent application contains a material error, which Applicant hereby respectfully requests to be corrected. Applicant also notes that this same error also appeared on the Notice of Acceptance of Application Under 35 U.S.C 371 and 37 CFR 1.495, see Exhibit 2; as well as on the U.S. Patent Application Publication No. US 2006/0140986 A1 dated June 29, 2006, see Exhibit 3; first page only presented here.

Applicant notes that the material error is in the PCT filing date for the International Application Number, PCT/EP2004/050967 for this 371 application, see Exhibit 4; first page only presented here. In the attached documents, Exhibits 1, 2, and 3, the filing date of this PCT application was erroneously printed as July 1, 2004, whereas the correct filing date is June 1, 2004. The typographical error in the month of filing incorrectly suggests that the PCT application did not and could not properly claim priority from the earlier filing of the foreign priority application in June of 2003.

In more specifics, Applicant respectfully directs the Office to the Filing Receipt currently in issue, where under the Domestic Priority Data as claimed by Applicant, the filing date was errantly printed 07/01/2004, not the appropriate 06/01/2004. Again, in more specifics, the identical error was also shown on the Notice of Acceptance of Application under 35 U.S.C 371 and 37 CFR 1.495, on which it incorrectly printed 07/01/2004 under the heading for "I.A. FILING DATE". Copies of the Filing Receipt and the Notice with corrections hand-noted thereon are attached, See Exhibits 1 and 2.

Applicant notes moreover that he duly filed a Petition for Republication of a Corrected Patent Application on August 25, 2006, See Exhibit 5. In the Petition, Applicant respectfully noted that the PCT application was timely filed on June 1, 2004; and subsequently requested republication with the correction of the material error. Applicant is now requesting correction of this typographical error in an updated Filing Receipt as well as throughout the application file wrapper.

Applicant respectfully submits that no fee is due with this request.

Dated: May 17, 2007

Respectfully Submitted,


Paul B. Scull, Registration No. 37,932
Attorney for Applicant
USPTO Customer No. 43,439

Berenbaum, Weinshienk & Eason, P.C.
370 Seventeenth Street., Suite 4800
Denver, CO 80202
Tel: 303.592.8378
Fax: 303.692.7610

EXHIBIT 1



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
10/562,392	12/19/2005	1615	450	264-011-USP	20	3

CONFIRMATION NO. 8090

45346
HENSLEY KIM & EDGINGTON, LLC
1660 LINCOLN STREET, SUITE 3050
DENVER, CO80264

FILING RECEIPT

Date Mailed: 04/18/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Fernando Bouffard Fita, Barcelona, SPAIN;

Power of Attorney: The patent practitioners associated with Customer Number 45346

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP04/50967 07/01/2004

Should be 06/01/2004

Foreign Applications

SPAIN P200301548 06/19/2003

If Required, Foreign Filing License Granted: 03/22/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/562,392**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine

Preliminary Class

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an International application under the Patent Cooperation Treaty (PCT). An International (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result in** a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to

espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

EXHIBIT 2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT.	ATTY. DOCKET NO.
10/562,392	Fernando Bouffard Fita	264-011-USP
INTERNATIONAL APPLICATION NO.		
PCT/EP04/50967		
L.A. FILING DATE	PRIORITY DATE	
07/01/2004	06/19/2003	
Should be 06/01/2004		
CONFIRMATION NO. 8090		
371 ACCEPTANCE LETTER		
 OC00000018345280		

Date Mailed: 04/18/2007

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

12/19/2005	12/19/2005
DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS	DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. THE DATE APPEARING ON THE FILING RECEIPT AS THE "FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE. The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Indication of Small Entity Status
- Copy of the International Application filed on 12/19/2005
- Copy of the International Search Report filed on 12/19/2005
- Preliminary Amendments filed on 12/19/2005
- Information Disclosure Statements filed on 12/19/2005
- Oath or Declaration filed on 12/19/2005
- Small Entity Statement filed on 12/19/2005
- Request for Immediate Examination filed on 12/19/2005
- U.S. Basic National Fees filed on 12/19/2005
- Priority Documents filed on 12/19/2005
- Specification filed on 12/19/2005

- Claims filed on 12/19/2005
- Abstracts filed on 12/19/2005

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

PATRICIA A BOOKER
Telephone: (703) 308-9140 EXT 204

PART 3 - OFFICE COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)

EXHIBIT 3

(19) United States

(12) Patent Application Publication
Fita(10) Pub. No.: US 2006/0140986 A1
(43) Pub. Date: Jun. 29, 2006(54) ANESTHETIC COMPOSITION FOR
TOPICAL ADMINISTRATION

Publication Classification

(76) Inventor: Fernando Bouffard Fita, Barcelona
(ES)(51) Int. Cl.
461K 9/00 (2006.01)
461K 31/24 (2006.01)
(52) U.S. Cl. 424/400; 514/537

Correspondence Address:
HENSLEY KIM & EDGINGTON, LLC
1660 LINCOLN STREET, SUITE 3050
DENVER, CO 80264 (US)

(21) Appl. No.: 10/562,392

(22) PCT Filed: Jul. 1, 2004

(86) PCT No.: PCT/EP04/50967

(30) Foreign Application Priority Data

Jun. 19, 2003 (ES) P200301548

(57) ABSTRACT

It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpyrrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of Tween-20; 0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a a high concentration on skin, a deep anesthetic effect and a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics.

EXHIBIT 4

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110423 A1

(51) International Patent Classification⁷: A61K 31/165.
31/167, 31/245, A61P 23/02

(21) International Application Number:
PCT/EP2004/050967

(22) International Filing Date: 1 June 2004 (01.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P200301548 19 June 2003 (19.06.2003) ES

(71) Applicant and
(72) Inventor: BOUFFARD FITA, Fernando [ES/ES]; Lope de Vega, 104 bajos, E-08005 Barcelona (ES).

(74) Agent: BARLOCCI, Anna; Zea Barriocci & Markvardsen, S.L., Balmes, 30 1^{er}, E-08007 Barcelona (ES).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIP0 (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, HE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(l)) for all designations

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/110423 A1

(54) Title: ANESTHETIC COMPOSITION FOR TOPICAL ADMINISTRATION

(57) Abstract: It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpyrrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of Tween-20; 0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a high concentration on skin, a deep anesthetic effect and a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics.

EXHIBIT 5

PTO/SB/87 (08-02)

Approved for use through 08/26/2006. GMB 0451-0221
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
CENTRAL FAX CENTER
AUG 25 2006

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

August 25, 2006
on _____
Date



Signature

Peter B. Scull

720-377-0773

Typed or printed name of person signing Certificate

In re U.S. Patent Application serial No. 10/562,392
 Title: Anesthetic composition for topical administration comprising lidocaine,
 prilocaine and tetracaine
 Filing Date : December 18, 2005
 Attorney Docket No. 284-011-USP

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

MAIL STOP PGPUB
 PTO Fax Number: 571-273-8300
 From: Peter B. Scull, Reg. No. 37,932

Transmitted herewith are:
 this Certificate of Transmission (1 page); and,
 Petition for Republication (2 pages) with two pages of exhibits.

Transmission Date : August 25, 2006
 Total Pages in Transmission: 6 pages

Please notify us immediately (720-377-0717) if there is a problem with receipt of this fax.

This collection of information is required by 37 CFR 1.8. The information is required to obtain a benefit by the public which is in the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

USTPO Central Facsimile No. (571) 273-8300
ATTENTION: MAIL STOP PGPUB

RECEIVED
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTRAL FAX CENTER

AUG 25 2006

In re Application of:

Applicant : Fernando Bouffard Fita	Confirmation No: 8090
Appn. No. : 10/562,392	Group Art Unit: not yet assigned
Filed : December 19, 2005	Examiner: not yet assigned
Title : ANESTHETIC COMPOSITION FOR TOPICAL ADMINISTRATION COMPRISING LIDOCAINA, PRILOCAINE AND TETRACAINA	

PETITION FOR REPUBLICATION OF CORRECTED PATENT APPLICATION
PURSUANT TO 37 C.F.R. § 1.221(b)

MAIL STOP PGPUB
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The above-referenced patent application was published on June 29, 2006 and contains a material mistake made by the U.S. Patent and Trademark Office, which is apparent from the Office records. The application contains a material mistake in the International filing date (or "PCT Filed" date) on the front page of the application. The correct International filing date (or "PCT Filed" date) is "June 1, 2004," not "July 1, 2004," as mistakenly shown on the front page of the application.

The materiality of this mistake lies in the relation of the International filing date (or "PCT Filed" date) to the priority date, whereby the errantly-published PCT Filed date of July 1, 2004, suggests that the PCT application was filed later than necessary to obtain priority, and thus presents the appearance that the PCT application did not appropriately claim priority from the earlier filing in June of 2003. This is indeed not the case because the PCT application was timely filed on June 1, 2004, and correctly claimed priority to the earlier case. Applicant also submits herewith supporting documents showing: 1) the relevant page of the original filing documents clearly showing the correct

Attorney Docket No: 284-011-USP


USTPO Central Facsimile No. (571) 273-8300
ATTENTION: MAIL STOP PGPUB

International PCT filing date (i.e. June 1, 2004); and II) the front page of the published application showing the incorrect International filing date (i.e. July 1, 2004).

Applicant is submitting this petition within the required two months of publication of the above-referenced application and respectfully requests republication of the above-referenced application to correct the material mistake pursuant to 37 CFR § 1.221(b). Applicant believes no fees or petitions are due with this filing. However, should any such fees or petitions be required, please consider this a request therefore and authorization to charge Deposit Account No. 50-3199 as necessary.

August 25, 2006

Respectfully submitted,



Peter B. Scull, Registration No. 37,932
Attorney for Applicant
HENSLEY KIM & EDGINGTON, LLC
USPTO Customer No. 45346
Tel: 720-377-0773
Fax: 720-377-0777

Attorney Docket No: 204-011-USP

US 2006140986A1

(19) United States

(22) Patent Application Publication (10) Pub. No.: US 2006/0140986 A1
Fitz (43) Pub. Date: Jun. 29, 2006(34) ANESTHETIC COMPOSITION FOR
TOPICAL ADMINISTRATION

Publication Classification

(51) Int. Cl.	
A61K 9/00	(2006.01)
A61K 31/24	(2006.01)

(52) U.S. Cl. 424/400; 514/537

(76) Inventor: Fernando Bradford Fitz, Berkeley
(US)Correspondence Address:
HENSLY KIM & EDGINGTON, LLC
1660 LINCOLN STREET, SUITE 3650
DENVER, CO 80264 (US)

(21) Appl. No.: 10/542,392

(22) PCT Pilot: *JM* ~~Jul 1, 2004~~

(36) PCT No.: PCT/EP04/02047

(30) Foreign Application Priority Data

Jun. 19, 2006 (28) P200601546

(37) ABSTRACT

It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methyl/glyceridemone; 2% of dimethyl sulphoxide; 0.05% of topical hydromorphone; 1.5% of guar gum; 1% of Tween-20; 0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a a high concentration on skin, a deep anaesthetic effect and a significantly more rapid onset of the anaesthetic effect than comparable transdermal anaesthetics.

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 264-011-USP
INTERNATIONAL APPLICATION NO. PCT/EP2004/050987		U.S. APPLICATION NO. (If known, see 37 CFR 1.6)
TITLE OF INVENTION <i>Anesthetic Composition for Topical Administration Comprising Lidocaine, Prilocaine and Tetracaine</i>		PRIORITY DATE CLAIMED 19 June 2003
APPLICANT(S) FOR DO/EO/US Fernando Bouffard Flis		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include Items (5), (6), (8) and (21) indicated below. <input type="checkbox"/> The US has been elected (Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input checked="" type="checkbox"/> has been communicated by the International Bureau. (courtesy copy) <input type="checkbox"/> is not required; as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(e)(2)). <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 164(d)(4). <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(e)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(e)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(e)(4)). <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <ul style="list-style-type: none"> Items 11 to 20 below concern document(s) or information included: <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A preliminary amendment. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.78. <input type="checkbox"/> A substitute specification. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter. (as part of Declaration) <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13(b)(2) and 37 CFR 1.821-1.825. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 164(d)(4). <input type="checkbox"/> A second copy of the English language translation of the International application under 35 U.S.C. 164(d)(4). 		

RECEIVED
CENTRAL FAX CENTER

AUG 25 2006

This collection of information is required by 37 CFR 1.414 and 1.461-1.462. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Correspondence is governed by 35 U.S.C. 132(a) and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete. Individuals are not required to respond to a collection of information unless it displays a valid OMB control number. Any comments or suggestions on the burden of this form you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 3